Forma Therapeutics Holdings, Inc. (Forma), Forma entered into an Agreement and Plan of Merger, dated August 31, 2022, with Novo Nordisk A/S, a Danish aktieselskab (Novo), and NNUS New Dev, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (Purchaser). Pursuant to the Merger Agreement, as of the Effective Time, the directors and officers of Purchaser immediately prior to the Effective Time became the directors and officers of the Surviving Corporation. As of the Effective Time, Frank D. Lee, Timothy P. Clackson, Marsha Fanucci, Wayne A.I. Frederick, Peter Kolchinsky, Arturo Molina, Thomas G. Wiggans, and Peter Wirth each ceased to be directors of Forma and members of any committee of Forma's board of directors.

These departures were not a result of any disagreement between Forma and the directors on any matter relating to Forma's operations, policies or practices. The directors of Purchaser immediately prior to the Effective Time were Steve Benz, Ulrich Christian Otte and Thomas Haagen. The executive officer of Purchaser immediately prior to the Effective Time was Ulrich Christian Otte.